Latham & Watkins advised Quotient
Sciences, the drug development and manufacturing accelerator, on its
acquisition of Arcinova, the UK based multiservice contract development and
manufacturing organization. With over 40 years of experience and 160 employees,
Arcinova provides drug substance, drug product and bioanalysis services to over
200 pharma and biotech customers worldwide.
The acquisition expands Quotient’s service
portfolio and will enable the integration of the drug substance, drug product
and clinical testing capabilities all under one organization. Quotient is a
portfolio company of private equity firm Permira. As part of the deal,
Arcinova’s minority equity partner, BFG, will exit the business, having backed
its growth since 2018.
Latham’s deal team was led by London
corporate partners Tom Evans and Neil Campbell, with associates Cigi
Puthuppally and Zaal Cama. Advice was also provided on regulatory and
compliance matters by a cross-border team consisting of Washington, D.C. partner
Ben Haas and associate Barrett Tenbarge, and London associates Frances Stocks
Allen and Oliver Mobasser; on intellectual property, data privacy and security
matters by London partner Deborah Kirk and associate Claudia Sousa; on EHS and
ESG matters by London partner Paul Davies and counsel Michael Green; on
anti-corruption matters by London counsel Daniel Smith, with associate Bryce
Williams; on real estate matters by London counsel Michael Beanland; on finance
matters by London associates Ben Wright and Carrie Chen; and on employment
matters by London partner Catherine Drinnan with associate Patrick Ritchie.